CHF 1.3
(2.45%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.67 CHF | 64.24% |
2022 | -4.67 CHF | -23.87% |
2021 | -3.77 CHF | -20.83% |
2020 | -3.12 CHF | 16.13% |
2019 | -3.72 CHF | -21.57% |
2018 | -3.06 CHF | -2450.0% |
2017 | -0.12 CHF | 95.73% |
2016 | -2.81 CHF | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q3 | -0.55 CHF | 11.67% |
2024 Q1 | 0.17 CHF | 126.15% |
2024 Q2 | -0.60 CHF | -452.94% |
2023 Q3 | 1.26 CHF | 222.33% |
2023 FY | - CHF | 64.24% |
2023 Q1 | -1.19 CHF | -9.17% |
2023 Q2 | -1.03 CHF | 13.45% |
2023 Q4 | -0.65 CHF | -151.59% |
2022 Q3 | -1.22 CHF | 2.4% |
2022 FY | - CHF | -23.87% |
2022 Q4 | -1.09 CHF | 10.66% |
2022 Q2 | -1.25 CHF | -11.61% |
2022 Q1 | -1.12 CHF | 25.83% |
2021 FY | - CHF | -20.83% |
2021 Q4 | -1.51 CHF | -79.76% |
2021 Q3 | -0.84 CHF | -1.2% |
2021 Q2 | -0.83 CHF | -31.75% |
2021 Q1 | -0.63 CHF | 38.83% |
2020 FY | - CHF | 16.13% |
2020 Q3 | -0.89 CHF | -71.15% |
2020 Q1 | -0.91 CHF | 15.74% |
2020 Q2 | -0.52 CHF | 42.86% |
2020 Q4 | -1.03 CHF | -15.73% |
2019 Q2 | -0.96 CHF | -18.52% |
2019 Q1 | -0.81 CHF | 0.0% |
2019 FY | - CHF | -21.57% |
2019 Q4 | -1.08 CHF | -20.0% |
2019 Q3 | -0.90 CHF | 6.25% |
2018 Q3 | -0.91 CHF | -51.67% |
2018 Q1 | -0.66 CHF | -224.53% |
2018 FY | - CHF | -2450.0% |
2018 Q4 | -0.81 CHF | 10.99% |
2018 Q2 | -0.60 CHF | 9.09% |
2017 FY | - CHF | 95.73% |
2017 Q1 | -0.96 CHF | 0.0% |
2017 Q2 | 0.78 CHF | 181.25% |
2017 Q4 | 0.53 CHF | 200.0% |
2017 Q3 | -0.53 CHF | -167.95% |
2016 FY | - CHF | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Addex Therapeutics Ltd | -0.14 CHF | -1092.857% |
BB Biotech AG | -3.77 CHF | 55.703% |
Basilea Pharmaceutica AG | 0.87 CHF | 291.954% |
Evolva Holding SA | -19.50 CHF | 91.436% |
Kuros Biosciences AG | -0.38 CHF | -339.474% |
Molecular Partners AG | -1.89 CHF | 11.64% |
Relief Therapeutics Holding AG | -8.35 CHF | 80.0% |
Santhera Pharmaceuticals Holding AG | 5.18 CHF | 132.239% |